Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective decreased by HC Wainwright from $25.00 to $22.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 83.03% from the company’s previous close.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Piper Sandler raised their target price on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. Finally, TD Cowen initiated coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.43.

Day One Biopharmaceuticals Stock Up 2.7%

Shares of Day One Biopharmaceuticals stock opened at $12.02 on Wednesday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -7.91 and a beta of -1.26. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $13.20. The company’s fifty day moving average is $10.63 and its 200 day moving average is $8.74.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The company had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%. As a group, equities analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the transaction, the insider owned 60,157 shares in the company, valued at $697,821.20. This represents a 8.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 6,065 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer owned 312,025 shares in the company, valued at $3,619,490. The trade was a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter worth approximately $39,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after purchasing an additional 1,029 shares during the period. Ameritas Investment Partners Inc. increased its position in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after buying an additional 2,264 shares during the last quarter. Quarry LP purchased a new stake in Day One Biopharmaceuticals in the third quarter worth $49,000. Finally, Entropy Technologies LP bought a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at $67,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and revenue beat: Q4 product revenues and full‑year receipts accelerated (Q4 net product revenues reported at $52.8M; FY net product revenues $155.4M) and overall Q4 revenue of $53.72M topped analyst estimates. This top‑line strength is the main positive catalyst. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Positive Sentiment: Reaffirmed and growth‑oriented 2026 guidance: management reiterated 2026 U.S. net product revenue guidance of $225–$250M and highlighted the Mersana acquisition (adds Emi‑Le into early clinical development), supporting a growth narrative beyond current OJEMDA™ sales. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Neutral Sentiment: Investor materials and management commentary available: the earnings slide deck, press release and full earnings call/transcript were posted for deeper diligence — useful for assessing product adoption, gross margin trajectory and commercialization expenses but not immediate market drivers. View Press Release / Slide Deck
• Neutral Sentiment: Transcript coverage: multiple transcripts (Seeking Alpha, InsiderMonkey) provide Q&A details on commercial rollout, supply and competition; these are helpful for modeling but require parsing for any near‑term changes to guidance assumptions. Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS miss and continued losses: reported EPS was −$0.21, missing consensus (−$0.17); the company still shows negative net margins and ROE, which keeps profitability timelines uncertain and could constrain valuation multiples until quarters of sustained margin improvement arrive. Day One Biopharmaceuticals Q4 2025 Earnings Highlights

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.